Related Experiment Video

Updated: Nov 26, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K

Chemotherapy and targeted therapeutics as maintenance of response in advanced non-small cell lung cancer

Melissa L Johnson1, Jyoti D Patel1

  • 1Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago IL.

Seminars in Oncology
|February 26, 2014
PubMed

Insights

Maintenance therapy for advanced non-small cell lung cancer (NSCLC) improves outcomes. Both switch and continuation strategies using newer agents offer enhanced efficacy and tolerability over standard treatments.

Area of Science:

  • Oncology
  • Medical Oncology
  • Clinical Trials

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality in the US.
  • Current standard platinum-based doublet therapy offers limited survival benefits for advanced NSCLC.
  • There is a need for improved treatment strategies to enhance outcomes in advanced NSCLC.

Purpose of the Study:

  • To review clinical trial data on maintenance strategies for advanced NSCLC.
  • To evaluate the efficacy and tolerability of switch and continuation maintenance therapies.
  • To assess the clinical implications and cost-effectiveness of these novel approaches.

Main Methods:

  • Review of available clinical trial data.
  • Analysis of switch maintenance strategies (non-cross-resistant drug after induction).
  • Analysis of continuation maintenance strategies (continuing non-platinum partner).

Main Results:

  • Maintenance strategies employing third-generation chemotherapies and small-molecule inhibitors show promise.
  • Both switch and continuation maintenance approaches are being evaluated for improved outcomes.
  • Comparative data on efficacy, tolerability, and cost-effectiveness are under review.

Conclusions:

  • Maintenance therapy represents a significant advancement in managing advanced NSCLC.
  • Switch and continuation strategies offer distinct approaches to prolonging patient survival.
  • Further assessment of clinical utility and economic value is crucial for optimal patient care.

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.9K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
884
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.2K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K